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The ac-K174 Tau as a biomarker for the early-diagnosis of Alzheimer 
Disease and a device for its detection
Hernández, C. Bachelor’s Degree in Biotechnology (2017-2021), Faculty of Biosciences
The Alzheimer’s Disease (AD) is the most common form of dementia, characterized by memory loss, cognitive decline and neurodegeneration. It is caused principally by the
accumulation of amyloid beta (Aß) peptide and Tau protein. Affecting over 35 million people worldwide, it is of an increased need the development of an early diagnostic
based on the discovery of early, affordable and available non-invasive biomarkers (1). Recent evidence has demonstrated that the acetylation on the lysine 174 of Tau is an
early critical pathological change to soluble Tau realized at the early stages in AD brains (Braak I-II), which leads to Tau accumulation and toxicity (2). However, the use of
technologies with high sensibility will be required for its detection as this biomarker is expected to appear in low concentrations. For this reason, the current research project
aims to validate the ac-K174 Tau as an early-diagnosis biomarker and to demonstrate its detection with a device proposal, as it could serve as a reliable biomarker for the
detection of AD during early stages.
INTRODUCTION
PROJECT TIMELINE
Figure 1: Representative scheme of the three-year ac-K174 Tau project workflow. The technical staff involved is divided in two 
groups: Group 1 (Simoa tasks) and Group 2 (Device development tasks).
OBJECTIVES
Validation of ac-K174 Tau as an early-diagnosis
AD biomarker.
• To establish the detectability of the ac-
K174 Tau biomarker.
• Temporal diagnostic of AD development
for determining ac-K174 Tau appearance
in AD.
• Determination of normal and pathologic
levels of the ac-K174 Tau.
Device design proposal for ac-K174 Tau
detection.
DEVICE PROPOSALac-K174 SIMOA VALIDATION AND DETECTION 
HYPOTHESIS
Can the acetylation of the lysine residue 174 of 
Tau protein be a biomarker for the early 
diagnosis of Alzheimer’s Disease?
Figure 2: A) Schematical representation of the procedure for the detection of ac-K174 in 
plasma and cerebrospinal fluid  (CSF) during the pilot and validation phase. The results 
recorded by Simoa HD-1 analyzer will shown in an intensity histogram (3) and later be 
analyzed with GraphPad Prism and R software. B) ELISA ac-K174 Tau kit.
EXPECTED RESULTS 
Figure 4: Graphical 
representation of the expected 
biomarker profile during healthy 
conditions and AD progression. 
Green line (Healthy control), 
Orange line (AD pathology), Blue 
line (MCI stage), Red line (AD 
clinically diagnosed). Blue circle 
(ac-K174), Purple circles 
(Aß40/Aß42), Green circles (Tau), 
Red circles (pTau181) and Brown 
circles (Nfl). 
CONCLUSIONS
The establishment of the ac-K174 Tau biomarker as a non-invasive early-stage AD
biomarker and the device could assist in the routine clinical practice:
• Improving the AD diagnosis at early stages facilitating the implementation of
available or potential treatments.
• Allowing the affected individuals to decide about important matters before
becoming demented.
• Providing time before the symptoms develop and identifying which individuals
should be evaluated for initiation of treatment in a more rapid and cheaper way
than with current technologies.
Figure 3: Schematics of the assembled test strip A) and exploded with the reader B) device 
drawings. C) Device channel 1; dsDNA scaffold, AC312 Ab, ac-K174 Tau floating on the plasma, 
2; Specifical binding to ac-K174, 3; Paramagnetic bead union and immunocomplex formation, 
4; Voltage supply and immunocomplex driving through nanopore into the opposing chamber, 
5; Temporary shift in the ionic current recorded as a detectable signal.
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